Porcine Vaccines Market Research Report: by Type (Inactivated Vaccines, DNA
Vaccines), by Disease Indication (Diarrhea, Swine Influenza), By End User - Global
Forecast Till 2023
The global Porcine Vaccines Market held a market value of USD 1910.7 million in 2017 and
is projected to grow at a CAGR of 7.1% over the forecast period. Porcine vaccines aid the
swine or hogs suffering from epidemic swine diseases. It also helps in improving overall
efficiency in protecting swine from deadly viruses, bacteria and increases the production
level of high-quality meat and gelatine. The increasing prevalence of swine diseases such as
PED (Porcine Epidemic Diarrhea), PRRS (Porcine Reproductive & Respiratory Syndrome),
swine influenza etc. are anticipated to drive the market growth during the forecast period.
Additionally, rising number of biotechnology companies, research institutions engaged in
research and development of porcine vaccines, and government initiatives for funding
agriculture and animal husbandry sector and increasing demand for porcine meat and
gelatine are likely to contribute to the market growth. For instance, by the world by per-
capita pig meat consumption, US has an average of 64.4 kilos of meat consumed in 2017.
According to National Pork Producers Council the pork production has an estimated USD
23.4 billion of gross output nationwide. However, high cost of maintaining vaccines may
hamper the market growth during the assessment period.
Get Sample Report at
Some of the prominent players in the global porcine vaccines market are Bayer AG, Bimeda,
Inc., Boehringer Ingelheim International GmbH, Ceva Sante Animale, Eli Lilly and Company,
Merck & Co., Inc., Sanofi S.A., Vetoquinol S.A., Zoetis, Inc., PBS Animal Health,
The global porcine vaccines market has been segmented into type, disease indication, and
By type, the market has been segmented into Inactivated